The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Murine Models to Evaluate Novel and Conventional Therapeutic Strategies for Cancer
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., Smigal, C., & Thun, M. J. (2006) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.56.2.106 · Cited by 5,314
Tight control of gene expression in mammalian cells by tetracycline-responsive promoters.
Gossen, M., & Bujard, H. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.12.5547 · Cited by 4,943
Alley, M. C., Scudiero, D. A., Monks, A. P., Hursey, M. L., Czerwiński, M., Fine, D. L., Abbott, B. J., Mayo, J. G., Shoemaker, R. H., & Boyd, M. R. (1988) · PubMed · Cited by 3,082
Regulation of cardiac hypertrophy by intracellular signalling pathways
Heineke, J., & Molkentin, J. D. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1983 · Cited by 1,866
Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death
Casares, N., Pequignot, M. O., Tesniere, A., Ghiringhelli, F., Roux, S., Chaput, N., Schmitt, E., Hamai, A., Hervas-Stubbs, S., Obeid, M., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050915 · Cited by 1,512
Freireich, E. J., Gehan, E. A., Rall, D. P., Schmidt, L. H., & Skipper, H. E. (1966) · PubMed · Cited by 1,382
Geran, R. I., Greenberg, N. H., MacDonald, M., Schumacher, A., & Abbott, B. J. (1972) · Cancer chemotherapy reports. Part 1 · Cited by 1,128
Quantitation of Differential Sensitivity of Human-Tumor Stem Cells to Anticancer Drugs
Salmon, S. E., Hamburger, A. W., Soehnlen, B., Durie, B. G. M., Alberts, D. S., & Moon, T. E. (1978) · New England Journal of Medicine · doi:10.1056/nejm197806152982401 · Cited by 970
Johnson, J. I., Decker, S., Zaharevitz, D., Rubinstein, L. V., Venditti, J. M., Schepartz, S., Kalyandrug, S., Christian, M., Arbuck, S., Hollingshead, M., et al. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1796 · Cited by 856
The mighty mouse: genetically engineered mouse models in cancer drug development
Sharpless, N. E., & DePinho, R. A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2110 · Cited by 661
Hoffman, R. M. (1999) · Investigational New Drugs · doi:10.1023/a:1006326203858 · Cited by 555
Role of NK cells in tumour growth and metastasis in beige mice
Talmadge, J. E., Meyers, K. M., Prieur, D. J., & Starkey, J. R. (1980) · Nature · doi:10.1038/284622a0 · Cited by 527
Self-citation(2003) · PubMed · Cited by 523
Transgenic mice harboring SV40 t-antigen genes develop characteristic brain tumors
Brinster, R. L., Chen, H. Y., Messing, A., van Dyke, T., Levine, A. J., & Palmiter, R. D. (1984) · Cell · doi:10.1016/0092-8674(84)90367-2 · Cited by 483
Orthotopic Models are Necessary to Predict Therapy of Transplantable Tumors in Mice
Killion, J. J., Radinsky, R., & Fidler, I. J. (1998) · Cancer and Metastasis Reviews · doi:10.1023/a:1006140513233 · Cited by 430
Self-citationHabu, S., Fukui, H., Shimamura, K., Kasai, M., Nagai, Y., Okumura, K., & Tamaoki, N. (1981) · The Journal of Immunology · doi:10.4049/jimmunol.127.1.34 · Cited by 426
Fidler, I. J. (1986) · CANCER AND METASTASIS REVIEW · doi:10.1007/bf00049529 · Cited by 373
Self-citationVon Hoff, D. D., Casper, J., Bradley, E., Sandbach, J., Jones, D., & Makuch, R. (1981) · The American Journal of Medicine · doi:10.1016/0002-9343(81)90859-7 · Cited by 370
Bogaards, J. J. P., Bertrand, M., Jackson, P., Oudshoorn, M. J., Weaver, R. J., Van Bladeren, P. J., & Walther, B. (2000) · Xenobiotica · doi:10.1080/00498250010021684 · Cited by 368
Cancer Modeling in the Modern Era
Van Dyke, T., & Jacks, T. (2002) · Cell · doi:10.1016/s0092-8674(02)00621-9 · Cited by 358
Kelland, L. R. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2003.11.028 · Cited by 352
Contributions of Human Tumor Xenografts to Anticancer Drug Development
Sausville, E. A., & Burger, A. M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3627 · Cited by 348
Kerbel, R. S. (2003) · Cancer Biology & Therapy · doi:10.4161/cbt.213 · Cited by 326
Orthotopic models of cancer for preclinical drug evaluation
Bibby, M. C. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2003.11.021 · Cited by 315
Lallemand-Breitenbach, V., Guillemin, M.-C., Janin, A., Daniel, M.-T., Degos, L., Kogan, S. C., Michael Bishop, J., & de Thé, H. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.7.1043 · Cited by 305
50 Years of Preclinical Anticancer Drug Screening: Empirical to Target-Driven Approaches
Suggitt, M., & Bibby, M. C. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.971.11.3 · Cited by 298
Clonogenic assay with established human tumour xenografts
Fiebig, H. H., Maier, A., & Burger, A. M. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2004.01.009 · Cited by 291
Chang, D. H., Liu, N., Klimek, V., Hassoun, H., Mazumder, A., Nimer, S. D., Jagannath, S., & Dhodapkar, M. V. (2006) · Blood · doi:10.1182/blood-2005-10-4184 · Cited by 271
Evidence for the Clonal Origin of Spontaneous Metastases
Talmadge, J. E., Wolman, S. R., & Fidler, I. J. (1982) · Science · doi:10.1126/science.6953592 · Cited by 255
Self-citationGenetically Engineered Models Have Advantages over Xenografts for Preclinical Studies
Becher, O. J., & Holland, E. C. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3827 · Cited by 243
Anticancer Drug Development: Preclinical Screening, Clinical Trials and Approval
Selwood, D. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602070 · Cited by 238
Corpet, D. E., & Pierre, F. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.06.006 · Cited by 230
Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development
Peterson, J. K., & Houghton, P. J. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2004.01.003 · Cited by 223
Rego, E. M., He, L.-Z., Warrell, R. P., Wang, Z.-G., & Pandolfi, P. P. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.180290497 · Cited by 194
The Use of Drugs in Combination for the Treatment of Cancer: Rationale and Results
DeVita, V. T., & Schein, P. S. (1973) · New England Journal of Medicine · doi:10.1056/nejm197305102881905 · Cited by 190
Fidler, I. J. (1991) · Cancer and Metastasis Review · doi:10.1007/bf00050794 · Cited by 183
Self-citationExperimental Models to Study Development and Function of the Human Immune System In Vivo
Legrand, N., Weijer, K., & Spits, H. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.4.2053 · Cited by 177
The response to chemotherapy of a variety of human tumour xenografts
Steel, G. G., Courtenay, V. D., & Peckham, M. J. (1983) · British Journal of Cancer · doi:10.1038/bjc.1983.1 · Cited by 167
Rodent tumor models in experimental cancer therapy
van der Kogel, A. J. (1988) · Radiotherapy and Oncology · doi:10.1016/0167-8140(88)90271-x · Cited by 167
Shoemaker, A. R., Gould, K. A., Luongo, C., Moser, A. R., & Dove, W. F. (1997) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(96)00041-8 · Cited by 152
Basu, G. D., Pathangey, L. B., Tinder, T. L., LaGioia, M., Gendler, S. J., & Mukherjee, P. (2004) · Molecular Cancer Research · doi:10.1158/1541-7786.632.2.11 · Cited by 151
CYTOCHROME P450 AND XENOBIOTIC RECEPTOR HUMANIZED MICE
Gonzalez, F. J., & Yu, A. (2005) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.100007 · Cited by 145
Cancer metastasis is selective or random depending on the parent tumour population
Talmadge, J. E., & Fidler, I. J. (1982) · Nature · doi:10.1038/297593a0 · Cited by 141
Self-citationCancer as a Complex Genetic Trait
Balmain, A. (2002) · Cell · doi:10.1016/s0092-8674(02)00622-0 · Cited by 139
Macchiarini, F., Manz, M. G., Palucka, A. K., & Shultz, L. D. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20051547 · Cited by 138
Mouse models in oncogenesis and cancer therapy
Céspedes, M. V., Casanova, I., Parreño, M., & Mangues, R. (2006) · Clinical & Translational Oncology · doi:10.1007/s12094-006-0177-7 · Cited by 130
TUMOR SUPPRESSOR GENE MUTATIONS IN MICE
Jacks, T. (1996) · Annual Review of Genetics · doi:10.1146/annurev.genet.30.1.603 · Cited by 105
Venditti, J. M., WESLEY, R. A., & Plowman, J. (1984) · Advances in pharmacology · doi:10.1016/s1054-3589(08)60263-x · Cited by 94
Preclinical drug development: rationale and methods.
Venditti, J. M. (1981) · PubMed · Cited by 93
Rodent tumor models in experimental cancer therapy
Kallman, R. F. (1987) · Cited by 90
Trials, Tribulations, and Trends in Tumor Modeling in Mice
Schuh, J. C. L. (2004) · Toxicologic Pathology · doi:10.1080/01926230490424770 · Cited by 89
Building ‘validated’ mouse models of human cancer
Hann, B. C., & Balmain, A. (2001) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(00)00283-0 · Cited by 78
Staquet, M. J., Byar, D. P., Green, S. B., & Rozencweig, M. (1983) · PubMed · Cited by 77
Shifting the cancer paradigm: must we kill to cure?
Schipper, H., Goh, C., & Wang, T. L. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.4.801 · Cited by 76
Clinical Correlations of Drug Sensitivity in the Human Tumor Stem Cell Assay
Salmon, S. E., Alberts, D. S., Durie, B. G. M., Meyskens, F. L., Jones, S. E., Soehnlen, B. J., Chen, H.-S. G., & Moon, T. E. (1980) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-642-81488-4_36 · Cited by 73
Varney, M. L., Olsen, K. J., Mosley, R. L., Bucana, C. D., Talmadge, J. E., & Singh, R. K. (2002) · PubMed · Cited by 63
Self-citationZubrod, C. G. (1972) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.69.4.1042 · Cited by 63
Scholz, C. C., Berger, D. P., Winterhalter, B. R., Henβ, H., & Fiebig, H. (1990) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(90)90196-z · Cited by 62
Development of biological diversity and susceptibility to chemotherapy in murine cancer metastases.
Talmadge, J. E., Benedict, K. L., Madsen, J. W., & Fidler, I. J. (1984) · PubMed · Cited by 60
Self-citationGenetic determinants of response to chemotherapy in transgenic mouse mammary and salivary tumors
Bearss, D. J., Subler, M. A., Hundley, J. E., Troyer, D. A., Salinas, R., & Windle, J. J. (2000) · Oncogene · doi:10.1038/sj.onc.1203275 · Cited by 46
Why drugs fail: of mice and men revisited.
Takimoto, C. H. M. (2001) · PubMed · Cited by 42
Evolving approaches to cancer drug discovery and development at the National Cancer Institute, USA
Sausville, E. A., & Feigal, E. G. (1999) · Annals of Oncology · doi:10.1023/a:1008333901925 · Cited by 41
Genetic background affects susceptibility to mammary hyperplasias and carcinomas in Apc(min)/+ mice.
Moser, A. R., Hegge, L. F., & Cardiff, R. D. (2001) · PubMed · Cited by 37
Barriers to Efficient Development of Cancer Therapeutics
Schein, P. S., & Scheffler, B. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0329 · Cited by 33
Nutritional?pharmacological combinations: A novel approach to reducing colon cancer incidence
Schwartz, B., Birk, Y., Raz, A., & Madar, Z. (2004) · European Journal of Nutrition · doi:10.1007/s00394-004-0462-6 · Cited by 32
Self-citationThomsen, M., Yacoub‐Youssef, H., & Marcheix, B. (2005) · Tissue Antigens · doi:10.1111/j.1399-0039.2005.00409.x · Cited by 22
Mouse cancer models as a platform for performing preclinical therapeutic trials
Weiss, B., & Shannon, K. (2003) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(02)00016-3 · Cited by 20
Brain, J. M., Saksena, A., & Laneuville, P. (2002) · Leukemia Research · doi:10.1016/s0145-2126(01)00181-3 · Cited by 20
Cellular senescence and cancer
(1999) · doi:10.1002/(sici)1096-9896(199901)187:1
Cited by
Tumour-targeting bacteria engineered to fight cancer
Zhou, S., Gravekamp, C., Bermudes, D., & Liu, K. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0070-z · Cited by 821
Preclinical Mouse Cancer Models: A Maze of Opportunities and Challenges
Day, C.-P., Merlino, G., & Van Dyke, T. (2015) · Cell · doi:10.1016/j.cell.2015.08.068 · Cited by 676
The Role of Adiponectin in Cancer: A Review of Current Evidence
Dalamaga, M., Diakopoulos, K. N., & Mantzoros, C. S. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1015 · Cited by 640
Mouse models of advanced spontaneous metastasis for experimental therapeutics
Francia, G., Cruz-Munoz, W., Man, S., Xu, P., & Kerbel, R. S. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3001 · Cited by 374
Tardi, P., Johnstone, S., Harasym, N., Xie, S., Harasym, T., Zisman, N., Harvie, P., Bermudes, D., & Mayer, L. (2009) · Leukemia Research · doi:10.1016/j.leukres.2008.06.028 · Cited by 356
Metadata
- Authors
- Talmadge, J. E., Singh, R. K., Fidler, I. J., & Raz, A.
- Venue
- The American Journal of Pathology
- Publisher
- Elsevier BV
- Published
- 2007-03
- Volume
- 170
- Issue
- 3
- Pages
- 793-804
- ISSN
- 0002-9440 (ISSN-L)
- OpenAlex
- W2035971989
- Cited by
- 468
- References
- 69
- FWCI
- 9.21
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.